Mother frantic to save clinical trial that could cure her daughter: 'The treatment is sitting in a fridge'
A rare, fatal disease called SPG50 affects fewer than 100 people globally, including 3-year-old Naomi Lockard. An experimental genetic therapy shows promise but is too expensive for most families. Naomi's mother, Rebekah Lockard, is raising funds for the therapy, which has shown success in stopping the disease's progression in clinical trials, but the trial has run out of funding.
Highlighted Terms
Related News
A rare, fatal disease called SPG50 affects fewer than 100 people globally, including 3-year-old Naomi Lockard. An experimental genetic therapy shows promise in halting the disease's progression but is too expensive for most. Naomi's mother, Rebekah Lockard, is fundraising to save her daughter's life. The therapy, developed by a parent of another SPG50 child, Terry Pirovolakis, has shown positive results in clinical trials but lacks funding for further treatment.
A rare, fatal disease called SPG50 affects fewer than 100 people globally, including 3-year-old Naomi Lockard. An experimental genetic therapy shows promise but is too expensive for most families. Naomi's mother, Rebekah Lockard, is raising funds for the therapy, which has shown success in stopping the disease's progression in clinical trials, but the trial has run out of funding.
A rare disease, SPG50, affects Naomi Lockard and her brother Jack. An experimental gene therapy shows promise but is expensive. Their mother, Rebekah Lockard, seeks funds to save her children's lives. The therapy aims to stop the progression of SPG50, a neurological disorder leading to paralysis and early death.